Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STS | P08842 | 4/20 | 0.39 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.37 |
| ▸ | OXTR | P30559 | 1/20 | 0.37 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.37 |
| ▸ | ENPP2 | Q13822 | 4/20 | 0.37 |
| ▸ | ATXN2 | Q99700 | 4/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21314452 | 0.88 | STS (0.41) | STSEHMT2OXTRAVPR1AENPP2 | |
| SCHEMBL21314453 | 0.88 | STS (0.41) | STSEHMT2OXTRAVPR1AENPP2 | |
| SCHEMBL20158218 | 0.87 | STS (0.42) | STSEHMT2ALDH1A1NPC1MAPT | |
| SCHEMBL21317536 | 0.85 | STS (0.50) | STSALDH1A1NPC1MAPTMAPK1 | |
| SCHEMBL30487540 | 0.81 | STS (0.35) | STSEHMT2OXTRAVPR1AENPP2 | |
| SCHEMBL21317519 | 0.79 | STS (0.41) | STSEHMT2OXTRAVPR1AALDH1A1 | |
| SCHEMBL21314539 | 0.74 | STS (0.45) | STSEHMT2ALDH1A1NPC1MAPT | |
| SCHEMBL21314540 | 0.74 | STS (0.45) | STSEHMT2ALDH1A1NPC1MAPT | |
| SCHEMBL30487464 | 0.72 | STS (0.37) | STSALDH1A1TP53POLBCNR1 | |
| SCHEMBL23747269 | 0.70 | STS (0.36) | STSALDH1A1ALOX15TP53POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11639353-B2 | Cyclobutanes- and azetidine-containing mono and spirocyclic compounds as αV integrin inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-05-02 | — | — | US | disclosed |
| WO-2018089355-A1 | CYCLOBUTANE- AND AZETIDINE-CONTAINING MONO AND SPIROCYCLIC COMPOUNDS AS ALPHA V INTEGRIN INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11639353-B2 | Cyclobutanes- and azetidine-containing mono and spirocyclic compounds as αV integrin inhibitors | ITGB1, ITGB2, ITGA1 | STS 1072/4885EHMT2 4076/4885OXTR 547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.